Denali Therapeutics Inc expected to post a loss of 80 cents a share - Earnings Preview

Denali Therapeutics

31/10/2023 02:03

* Denali Therapeutics Inc  DNLI.OQ   DNLI.O  is expected
to show a
rise in quarterly revenue when it reports  results 
    * The South San Francisco California-based  company is
expected to
report  a 214.2% increase in revenue to $11.181 million from
$3.56 million a year ago, according to the mean estimate from 13
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Denali Therapeutics
Inc
is for a loss of 80 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 15 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Denali
Therapeutics Inc is $50​, above​ its last closing price
of $18.40. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.60       -0.68      1.30      Beat    290.1
 Mar. 31 2023  -0.71       -0.70      -0.80     Missed  -13.6
 Dec. 31 2022  -0.77       -0.79      -0.75     Beat    5.1​
 Sep. 30 2022  -0.78       -0.81      -0.84     Missed  -4.2
 ​​Jun.        -0.53       -0.55      -0.48     Beat    12.6
 30 2022                                                
 Mar. 31 2022  -0.51       -0.51      -0.53     Missed  -4.3​
 Dec. 31 2021  -0.43       -0.41      -0.62     Missed  -49.8
 Sep. 30 2021  -0.52       -0.47      -0.69     Missed  -45.6
 This summary was machine generated October 31 at 02:02 GMT.  All
figures in US dollars  unless otherwise stated